Immunome's Chief Legal Officer Sandra Stoneman Awarded 38,250 RSUs and 76,500 Stock Options on July 23, 2026

Details of Executive Equity Award and Vesting Terms

On July 23, 2026, Sandra Stoneman, Immunome’s Chief Legal Officer and General Counsel, was granted equity compensation comprising 38,250 restricted stock units and 76,500 employee stock options. These awards were granted at no cost to her, aligning with typical equity compensation practices within the biopharmaceutical industry.

The RSUs vest over four years with a cliff schedule, where 25% of the units vest and convert to common stock on each anniversary of the grant date, contingent on Stoneman’s continuous employment. The stock options vest with 25% becoming exercisable on July 23, 2027, and the remaining options vest monthly in equal increments over the following 36 months, subject to continued service.

Exercise Price and Expiration of Stock Options

The employee stock options granted carry an exercise price of $22.01 per share, defining the price at which Stoneman can purchase Immunome common stock upon exercising the options. These options have a 10-year term, expiring on July 22, 2036, allowing a lengthy period for potential exercise depending on vesting and market conditions.

The $22.01 exercise price was set at the time of grant on July 23, 2026. Options that remain out of the money—where the stock price is below the exercise price—would hold no intrinsic value and likely remain unexercised. The extended expiration period provides flexibility for exercise timing, subject to vesting and regulatory compliance.

Increase in Beneficial Ownership Following Equity Grant

Following this equity award, Sandra Stoneman’s direct beneficial ownership of Immunome common stock increased to 43,805 shares. This total includes fully vested shares, vested RSUs converted to common stock, and newly granted RSUs still subject to vesting. This disclosure reflects her ownership as of the transaction date, indicating her stake and alignment with shareholder interests.

Her direct beneficial ownership means she holds these securities personally rather than through trusts or other entities. Regulatory reporting requirements provide investors with transparency on insider holdings and potential conflicts. Executive ownership levels often signal confidence in company prospects but should be analyzed alongside broader compensation and market factors.

Regulatory Filing and Insider Trading Compliance

The transaction was reported under Section 16(a) of the Securities Exchange Act of 1934, mandating officers, directors, and significant shareholders to disclose changes in beneficial ownership. Stoneman’s Form 4 filing was submitted on July 27, 2026, within two business days of the transaction, ensuring timely investor access to insider equity compensation information.

The filing confirmed the transaction was not executed under a Rule 10b5-1 trading plan, indicating it was a routine equity grant rather than a pre-planned sale schedule. Such grants are common for periodic executive compensation awards.

Equity Awards as Part of Executive Incentive Programs

The combination of restricted stock units and stock options awarded to Stoneman reflects a hybrid compensation approach prevalent in biopharmaceutical and technology sectors. RSUs provide direct equity value upon vesting, while options offer potential upside if the stock price appreciates beyond the exercise price. This mix balances immediate value with long-term incentive alignment.

Public company compensation committees use equity grants to attract and retain executives in competitive industries. Vesting schedules encourage retention and align management incentives with shareholder value creation and strategic goals.

Company Profile and Executive Role

Immunome Inc., headquartered at 18702 N. Creek Parkway, Suite 100, Bothell, Washington, is a NASDAQ-listed biopharmaceutical firm (ticker: IMNM). The Chief Legal Officer and General Counsel role is vital for overseeing legal compliance, risk management, regulatory affairs, and governance. The equity grant underscores the company’s emphasis on this leadership position in driving its strategic initiatives.

Executive compensation and insider transactions provide insights into leadership stability and company direction. The timing, size, and terms of equity grants often reflect established compensation plans rather than performance-contingent awards.

Accuracy and Legal Compliance of Transaction Filing

Stoneman’s Form 4 filing dated July 27, 2026, serves as an official declaration of the securities transaction under federal law. False statements or omissions in such filings are criminal offenses under 18 U.S.C. § 1001 and 15 U.S.C. § 78ff(a). The filing details the transaction date, security types, quantities, prices, and vesting terms, providing a transparent record accessible via the SEC’s EDGAR system.

The filing also explains the vesting schedules for both RSUs and stock options, ensuring investors and regulators have full disclosure of insider compensation timing and conditions.

Investor Considerations on Insider Holdings

Investors should monitor the vesting and potential exercise of these equity awards by Stoneman. As RSUs vest and convert to common stock, her direct shareholding and voting power will increase. Similarly, exercising vested stock options will further augment her ownership. Any subsequent sales must be reported in future Form 4 or Form 5 filings.

The $22.01 exercise price serves as a benchmark for assessing stock performance relative to executive compensation. If Immunome’s stock price rises above this level, the options gain value and incentivize continued executive performance. Conversely, if the stock price remains below the exercise price, options may expire unexercised. Changes in insider ownership are often scrutinized by investors as indicators of management’s confidence in company prospects.